| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Quercetin pentaacetate targets the F-protein (fusion protein) of respiratory syncytial virus (RSV). The compound interacts with the F-protein, forming stable complexes with low binding energy, which effectively blocks viral adhesion to host cell surfaces. This antiviral mechanism prevents RSV from entering cells and initiating infection. In addition to its antiviral activity, quercetin pentaacetate inhibits COX-2 (cyclooxygenase-2) expression and PGE2 (prostaglandin E2) production in macrophages, indicating anti-inflammatory activity. The compound may also interact with other cellular targets involved in inflammation and oxidative stress. As a flavonoid derivative, quercetin pentaacetate shares some of the biological activities of quercetin, including antioxidant and anti-inflammatory properties.
|
|---|---|
| ln Vitro |
Quercetin pentaacetate (0–40 μM) exhibits a clear suppression of COX-2 gene expression and PGE2-induced PGE2 synthesis in RAW 264.7 cells co-treated with L-NAME/LPS or NLA/LPS[2].
In vitro, quercetin pentaacetate demonstrates antiviral activity against respiratory syncytial virus (RSV) by inhibiting viral adhesion to cell surfaces. The compound interacts with the viral F-protein, blocking the fusion of the viral envelope with the host cell membrane and preventing viral entry. At concentrations of 0-40 μM, quercetin pentaacetate shows obvious inhibition of LPS-induced PGE2 production and COX-2 gene expression in RAW 264.7 macrophages, particularly in NLA/LPS or L-NAME/LPS co-treated cells. The compound also exhibits antiplatelet effects, inhibiting collagen- and arachidonic acid-induced platelet aggregation and ATP release. These in vitro activities highlight the compound's potential as an antiviral and anti-inflammatory agent. |
| ln Vivo |
In vivo studies of quercetin pentaacetate are limited, as the compound is primarily used as a research tool in in vitro and cell-based assays. The in vivo activity of quercetin pentaacetate would be expected to reflect its antiviral and anti-inflammatory properties, although the acetylated derivative may have different pharmacokinetic properties compared to quercetin. The compound's improved lipophilicity may enhance its oral bioavailability and tissue distribution. Animal studies would be needed to evaluate the efficacy of quercetin pentaacetate in RSV infection models and inflammatory disease models. The compound's potential as a therapeutic agent remains to be fully explored in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for quercetin pentaacetate are performed to assess its interaction with the RSV F-protein. Surface plasmon resonance (SPR) or biolayer interferometry (BLI) can be used to measure the binding affinity (Kd) of the compound to recombinant F-protein. Molecular docking studies are also employed to predict the binding mode and interaction energy. For COX-2 inhibition, enzyme activity assays are performed using purified COX-2 enzyme and arachidonic acid as substrate, with PGE2 production measured by ELISA. The IC50 for COX-2 inhibition is determined from concentration-response curves. The assay includes positive controls (e.g., celecoxib for COX-2) and negative controls (vehicle only).
|
| Cell Assay |
In vitro cell-based assays for quercetin pentaacetate are performed using RSV-susceptible cell lines (e.g., HEp-2 or A549 cells) to assess antiviral activity. Cells are infected with RSV and treated with various concentrations of the compound (0-40 μM). Viral replication is measured by plaque reduction assay, qRT-PCR for viral RNA, or immunofluorescence staining for viral proteins. The EC50 for antiviral activity is determined. For anti-inflammatory studies, RAW 264.7 macrophages are stimulated with LPS in the presence or absence of the compound. PGE2 levels in the culture supernatant are measured by ELISA. COX-2 expression is assessed by Western blotting or qRT-PCR. Cytotoxicity is evaluated using MTT or LDH release assays to determine the selectivity index.
|
| Animal Protocol |
In vivo animal studies with quercetin pentaacetate are not extensively documented. For antiviral studies, mice or cotton rats infected with RSV could be treated with the compound via oral or intraperitoneal administration. Endpoints would include viral load in lung tissues (by plaque assay or qRT-PCR), lung histopathology, and inflammatory cytokine levels in bronchoalveolar lavage fluid (BALF). For anti-inflammatory studies, animal models of inflammation (e.g., carrageenan-induced paw edema, LPS-induced sepsis) could be used. Doses, routes of administration, and treatment schedules would need to be optimized. The compound's in vivo efficacy and safety profile remain to be fully characterized in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of quercetin pentaacetate have not been extensively characterized. As a acetylated flavonoid, the compound is expected to have improved lipophilicity and membrane permeability compared to quercetin, potentially enhancing oral absorption. The acetate groups may be hydrolyzed in vivo to release the parent quercetin, contributing to the compound's biological activity. Quercetin pentaacetate is likely metabolized in the liver and excreted via the kidneys and bile. The compound's stability in biological fluids and its plasma protein binding would need to be determined experimentally. For research use, the compound is typically dissolved in DMSO and diluted in appropriate buffers or media.
|
| Toxicity/Toxicokinetics |
Quercetin pentaacetate is a research chemical with limited toxicological data available. As a derivative of the natural flavonoid quercetin, which is generally recognized as safe, the compound is expected to have low toxicity. However, the acetylated form may have different toxicological properties. Standard safety precautions should be followed when handling the compound, including the use of personal protective equipment. The compound should be stored at appropriate conditions (typically -20°C) and protected from light. No specific toxicological studies have been reported in the literature. The compound is for research use only and not for human or veterinary applications.
|
| References |
|
| Additional Infomation |
It has been reported that Byrsonima coccolobifolia contains quercetin pentaacetate, and there is relevant data available.
Quercetin pentaacetate is a synthetic derivative of quercetin, a flavonoid found in many fruits and vegetables with known antioxidant, anti-inflammatory, and antiviral properties. The acetylation of quercetin enhances its lipophilicity and stability, making it a useful research tool for studying the biological activities of flavonoids and their derivatives. The compound's ability to inhibit RSV adhesion and its anti-inflammatory effects make it a candidate for further investigation as a potential therapeutic agent for viral infections and inflammatory diseases. Quercetin pentaacetate is available from chemical suppliers for research purposes only. Further studies are needed to fully characterize its pharmacological profile and therapeutic potential. |
| Molecular Formula |
C25H20O12
|
|---|---|
| Molecular Weight |
512.42
|
| Exact Mass |
512.095
|
| CAS # |
1064-06-8
|
| PubChem CID |
14005
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.45g/cm3
|
| Boiling Point |
666.4ºC at 760 mmHg
|
| Flash Point |
284.7ºC
|
| Vapour Pressure |
1.27E-17mmHg at 25°C
|
| Index of Refraction |
1.6
|
| LogP |
3.086
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
37
|
| Complexity |
998
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JQUHMSXLZZWRHU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H20O12/c1-11(26)32-17-9-20(35-14(4)29)22-21(10-17)37-24(25(23(22)31)36-15(5)30)16-6-7-18(33-12(2)27)19(8-16)34-13(3)28/h6-10H,1-5H3
|
| Chemical Name |
[2-acetyloxy-4-(3,5,7-triacetyloxy-4-oxochromen-2-yl)phenyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9515 mL | 9.7576 mL | 19.5152 mL | |
| 5 mM | 0.3903 mL | 1.9515 mL | 3.9030 mL | |
| 10 mM | 0.1952 mL | 0.9758 mL | 1.9515 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
